This HTML5 document contains 83 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/AHFS/
n9http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/mesh/concept/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00291/identifier/national-drug-code-directory/
n8http://linked.opendata.cz/resource/drugbank/dosage/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00291/identifier/chemspider/
n17http://bio2rdf.org/drugbank:
n26http://linked.opendata.cz/resource/drugbank/drug/DB00291/identifier/chebi/
admshttp://www.w3.org/ns/adms#
n24http://linked.opendata.cz/resource/drugbank/drug/DB00291/identifier/wikipedia/
n28http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00291/identifier/pharmgkb/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://linked.opendata.cz/resource/drugbank/medicinal-product/
n5http://linked.opendata.cz/ontology/drugbank/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/mesh/
n15http://www.drugs.com/cdi/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00291/identifier/pubchem-compound/
n29http://www.rxlist.com/cgi/generic2/
n10http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n22http://linked.opendata.cz/resource/drugbank/drug/DB00291/identifier/kegg-drug/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00291/identifier/pubchem-substance/
n7http://linked.opendata.cz/resource/atc/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00291/identifier/drugbank/
n6http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00291
rdf:type
n5:Drug
n5:description
A nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and nonmalignant diseases. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
n5:dosage
n8:271B4B90-363D-11E5-9242-09173F13E4C5 n8:271B4B91-363D-11E5-9242-09173F13E4C5
n5:generalReferences
# Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, Hines J, Threatte GA, Larson RA, Cheson BD, Schiffer CA: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000 Dec 14;343(24):1750-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11114313 # Yang K, Tan J, Wu T: Alkylating agents for Waldenstrom's macroglobulinaemia. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD006719. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19160296# Foon KA, Hallek MJ: Changing paradigms in the treatment of chronic lymphocytic leukemia. Leukemia. 2010 Mar;24(3):500-11. Epub 2009 Dec 24. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20033051
n5:group
approved
n5:halfLife
1.5 hours
n5:indication
For treatment of chronic lymphatic (lymphocytic) leukemia, childhood minimal-change nephrotic syndrome, and malignant lymphomas including lymphosarcoma, giant follicular lymphoma, Hodgkin's disease, non-Hodgkin's lymphomas, and Waldenström’s Macroglobulinemia.
n5:manufacturer
n9:271B4B8E-363D-11E5-9242-09173F13E4C5
owl:sameAs
n17:DB00291 n28:DB00291
dcterms:title
Chlorambucil
adms:identifier
n19:46506842 n20:PA448926 n21:2708 n22:D00266 n23:0173-0635-35 n24:Chlorambucil n25:DB00291 n26:28830 n27:2607
n5:mechanismOfAction
Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations.
n5:packager
n9:271B4B8B-363D-11E5-9242-09173F13E4C5 n9:271B4B8C-363D-11E5-9242-09173F13E4C5 n9:271B4B8D-363D-11E5-9242-09173F13E4C5
n5:routeOfElimination
Chlorambucil is extensively metabolized in the liver primarily to phenylacetic acid mustard. The pharmacokinetic data suggests that oral chlorambucil undergoes rapid gastrointestinal absorption and plasma clearance and that it is almost completely metabolized, having extremely low urinary excretion.
n5:synonym
CHLORAMBUCIL Leukeran Chloraminophen gamma-[P-Di(2-chloroethyl)aminophenyl]butyric acid 4-(P-Bis(beta-chloroethyl)aminophenyl)butyric acid γ-[p-di(2-chloroethyl)aminophenyl]butyric acid 4-(p-bis(β-chloroethyl)aminophenyl)butyric acid Ambochlorin N,N-di-2-chloroethyl-γ-p-aminophenylbutyric acid 4-[p-[bis(2-chloroethyl)amino]phenyl]butyric acid Phenylbutyric Acid Nitrogen Mustard N,N-Di-2-chloroethyl-gamma-P-aminophenylbutyric acid
n6:hasAHFSCode
n13:10-00-00
n5:foodInteraction
Take on an empty stomach. Drink liberally. Echinacea should be used with caution, if at all, in patients receiving therapeutic immunosuppressants. Monitor for reduced efficacy of the immunosuppressant during concomitant use. Food reduces bioavailability.
n5:proteinBinding
99%
n5:synthesisReference
Phillips, A. P. and Mentha, J.W.; U.S.Patent 3,046,301; July 24, 1962; assigned to Burroughs Wellcome & Co. (U.S.A.) Inc.
n3:hasConcept
n4:M0004118
foaf:page
n15:chlorambucil.html n29:leukeran.htm
n5:IUPAC-Name
n10:271B4B96-363D-11E5-9242-09173F13E4C5
n5:InChI
n10:271B4B9C-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n10:271B4B9B-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n10:271B4B98-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n10:271B4B99-363D-11E5-9242-09173F13E4C5
n5:SMILES
n10:271B4B9A-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n10:271B4B94-363D-11E5-9242-09173F13E4C5 n10:271B4BAC-363D-11E5-9242-09173F13E4C5
n5:logP
n10:271B4B92-363D-11E5-9242-09173F13E4C5 n10:271B4B95-363D-11E5-9242-09173F13E4C5 n10:271B4BAE-363D-11E5-9242-09173F13E4C5
n5:logS
n10:271B4B93-363D-11E5-9242-09173F13E4C5
n5:pKa
n10:271B4BAF-363D-11E5-9242-09173F13E4C5
n6:hasATCCode
n7:L01AA02
n5:H-Bond-Acceptor-Count
n10:271B4BA2-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n10:271B4BA3-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n10:271B4B9D-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n10:271B4B9E-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n10:271B4BA0-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n10:271B4B9F-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n10:271B4BA1-363D-11E5-9242-09173F13E4C5
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
305-03-3
n5:category
n5:containedIn
n12:271B4B8F-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n10:271B4BA8-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n10:271B4BAA-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n10:271B4BAB-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n10:271B4BAD-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n10:271B4BA7-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n10:271B4BA6-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n10:271B4BA9-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n10:271B4B97-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n10:271B4BA4-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n10:271B4BA5-363D-11E5-9242-09173F13E4C5